MAGEA3 and neoplasm: At tumour sites, 33 (89%), 13 (35%), 16 (43%), 11 (30%), 10 (27%), and seven (19%) specimens expressed KK-LC-1, MAGE-A1, MAGE-A3, MAGE-A4, SSX4, and NY-ESO-1, respectively.